News & Updates

Adding nipocalimab to standard-of-care (SoC) treatment significantly improves Myasthenia Gravis-Activities of Daily Living (MG-ADL) scores in patients with generalized MG (gMG), according to the pivotal phase III Vivacity-MG3 study presented at EAN 2024.

Prenatal exposure to fine particulate matter appears to put newborns at risk of cerebral palsy, as shown in a study.

The treatment effect of omaveloxolone in halting progression, based on change in mFARS score, is particularly pronounced in individuals with Friedreich's ataxia who had disease onset at ≤15 years of age, suggests a post hoc subgroup analysis of MOXIe Part 2 presented at EAN 2024.

Benralizumab offers more sustained and earlier elimination of oral GCs vs mepolizumab in patients with relapsing or refractory EGPA, suggests a post hoc analysis of the MANDARA study presented at EULAR 2024

The use of Janus kinase (JAK) inhibitors in the treatment of major autoimmune diseases appears to reduce the risk of age-related macular degeneration (AMD) for people above 40 years of age, according to a study.

Ethnic differences emerge in stroke patterns within Singapore, with a study finding showing that Indians have lower rates of haemorrhagic stroke and a lower proportion of female patients compared with the Chinese and Malay populations.

Patients with cirrhosis and nonvalvular atrial fibrillation (AF) who initiated rivaroxaban are more likely to experience major haemorrhage than those administered with apixaban, according to a study. However, the rates of ischaemic events and death are similar between the two treatment groups.